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As it is unclear if hereditary factors affect breast cancer survival, this was compared using fertility and cancer registry data, among all
women so diagnosed during 1961–1999 in Sweden, having a child with childhood cancer (p20 years of age; n¼254) and with that
of other women (n¼74781). Those having a child with a childhood malignancy had a significantly worse survival than other women,
relative risk (RR)¼1.25, 95% CI 1.02–1.55, Po0.04, adjusted for age at diagnosis, year of diagnosis, parity and time since last
pregnancy. Childhood sarcomas or acute myeloid leukaemia seemed to be most associated with a worse survival in the mother
(RR¼1.38 and 1.69, respectively). The lower survival of the mother was present for breast cancer diagnosed both before and after
50 years of age. The Li–Fraumeni syndrome and possibly other genetic disorders may lower breast cancer survival.
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Only a minority of cases of breast cancer have a hereditary
background. Hereditary factors could affect tumour biology and
disease prognosis and it has been suggested that breast
cancer patients having p53 germline mutations have an especially
bad prognosis (Olsson, 2000, 2001). In the present study, survival
has been compared in women with breast cancer with and
without having a child with a paediatric tumour, using the latter as
a surrogate measure for such hereditary factors as Li–Fraumeni
syndrome (Li and Fraumeni, 1969; Malkin et al, 1990;
Varley et al, 1997).
MATERIALS AND METHODS
Women with at least one child and a breast cancer diagnosis
during 1961–1999 were identified by means of the unique personal
identification numbers and the National Swedish Cancer register,
fertility register and Swedish national censuses (n¼75035)
together with deaths, emigrations and tumours in their children.
Only primary tumours were considered and no information about
recurrences or development of secondary tumours is available. The
women were followed from breast cancer diagnosis to the first
event of emigration, death or 31 December 2001.
In addition, deaths after breast cancer in women having a child
with any of the diagnosis of sarcoma, brain tumour, lymphoma,
acute leukaemia or myeloid leukaemia p20 years of age, compared
to women not having any child with cancer were analysed by
means of Cox proportional hazard modelling. We also adjusted for
the number of children and time since last childbirth, which are
known to affect prognosis. However, results by childhood tumour
type should be interpreted with caution, as there were only few
women in each relevant group. All analyses were stratified for the
women’s year and age of diagnosis.
Kaplan–Meier survival curves for women having a child with
any of the specified diagnoses and women not having any child
with cancer were also estimated. To have groups with a
comparable year and age of diagnosis, four women who did not
have any child with cancer matched for year and age of diagnosis
were randomly selected for each woman who had a child with
cancer. Kaplan–Meier survival curves were also estimated for
women with a diagnosis at o50 and X50 years of age, respectively.
The Research Ethics Committee of Lund University approved
this study.
RESULTS
A total of 254 women with breast cancer having a child with
malignancy were identified, of which 33 were diagnosed before the
childhood tumour. Brain tumours, leukaemia, lymphomas and
sarcoma were the commonest childhood tumours.
As shown in Table 1, the relative risk (RR) of dying for a woman
with breast cancer having a child with cancer vs not having a child
with cancer is 1.26 (95% CI 1.02–1.56). Risk was highest if the
child had acute myeloid leukaemia (RR¼1.71, 95% CI 0.75–3.89)
or sarcoma (RR¼1.42, 95% CI 0.88–2.28). Adjusting for number
of children and time since last childbirth only marginally changed
the risk estimates. Censoring the follow-up of all women at 65
years of age did not influence the results.
Figure 1 shows the survival curve for all women. The survival
difference was present both in younger (o50 years) and older
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y(X50 years at diagnosis) patients and seemed to persist beyond 15
years of follow-up. However, the difference occurred earlier and
was more pronounced in younger patients.
DISCUSSION
In this population-based national registry study, a worse breast
cancer survival was found for women also having an offspring with
a paediatric malignancy compared to other parous women not
having a child with malignancy. The most plausible explanation is
that a genetic factor, such as p53 germline mutations, in a small
subgroup of the first-mentioned women, also affects tumour
biology causing the worse survival, as we postulated before
(Olsson, 2001). Breast cancer is the commonest tumour disease in
the Li–Fraumeni syndrome, cumulatively with about a 50%
lifetime risk in female carriers (Eeles et al, 1993; Chompret et al,
2000; Varley, 2003). The childhood tumours such as sarcoma,
brain tumours and leukaemia described here are well-recognised
within the syndrome (Chompret et al, 2000).
In this registry study, we lacked information about tumour stage
or other biological factors related to prognosis and about therapy.
We were, however, able to adjust for age at diagnosis, birth year,
number of children and time since last childbirth, as breast cancer
diagnosed in pregnancy or in its close proximity has an especially
poor prognosis (Guinee et al, 1994; Bladstrom et al, 2003); this
only marginally changed the risk estimates. It is, however, unlikely
that access to different therapy or a biological factor randomly
could account for the findings.
Being a nationwide study, overall survival was estimated
and not breast cancer-specific survival. Intercurrent disease
and death could have affected survival in women with
diagnosis at older ages (analysed above 60 years of age) but
would have no major effect in younger women. Thus, the smaller
effect seen for older patients could be due to differences in
intercurrent deaths.
There is no reason to suspect inclusion bias that an offspring
having childhood cancer is related to the likelihood of a
woman being identified by the registries. Most childhood
cancers occurred before the breast cancer diagnoses in
mothers, but available evidence gives little support to the notion
that a stress reaction or grief can affect the prognosis of breast
cancer. However, an alternative hypothesis is that the shared
environmental effects might also contribute to an increased
mortality risk.
Further studies with tumour stage, hormone receptor status,
nuclear grade, erbb2 status, therapy and p53 germline mutation
status may elucidate this link between childhood cancer and breast
cancer. Our results suggest that data on whether a woman has had
an offspring with childhood cancer have prognostic value.
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Table 1 Relative risk of death in women with breast cancer not having a child with malignancy and in women with breast cancer having a child with a
malignancy according to childhood tumour type
Group
Number of
women
a
Unadjusted RR (95% CI)
P-value
Adjusted
b RR (95% CI)
P-value
Child without cancer 74781 1 1
Child with cancer 254 1.26 (1.02–1.56) 1.25 (1.02–1.55)
0.03 0.04
By specified tumour type
Sarcoma 43 1.42 (0.88–2.28) 1.38 (0.86–2.22)
0.15 0.18
Brain tumour 81 1.19 (0.80–1.76) 1.18 (0.80–1.75)
0.39 0.40
Lymphoma 58 1.31 (0.86–1.99) 1.28 (0.85–1.96)
0.21 0.24
Acute lymphatic leukaemia 34 0.88 (0.44–1.73) 0.89 (0.44–1.81)
0.71 0.75
Myeloid leukaemia 20 1.71 (0.75–3.89) 1.69 (0.74–3.85)
0.20 0.21
Monocytic leukaemia and other unspecified leukaemias 21 1.29 (0.66–2.50) 1.30 (0.67–2.54)
0.46 0.43
RR¼relative risk.
aOne woman had a child with lymphoma and one child with acute lymphatic leukaemia; and one woman had one child with sarcoma, one child with brain
tumour and one child with lymphoma; 33 women had the breast cancer diagnosis before the diagnosis of the child; and 221 women had the breast cancer diagnosis after the
diagnosis of the child.
bAdjusted for number of children and time since last childbirth.
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Figure 1 Kaplan–Meier survival curves for women with and without a
child with a malignant tumour given for all women.
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